MarginsXMarginsX
Home › Markets › Health Care › LCTX

Lineage Cell Therapeutics Inc. (LCTX)

LCTX trades on NYSE in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.7951
-13.07% on the day
Market cap
$201.1M
Micro cap
Revenue · 2025
$14.6M
+53.2% on 2024
Net income · 2025
-$63.5M
-436.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/876343/000119312526093992/0001193125-26-093992-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerLCTX on NYSE
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0000876343
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inCA

Financials · 2025

LineValue
Revenue$14.6M
Net income-$63.5M
Operating income-$36.6M
Net margin-436.5%
Operating margin-251.6%
Revenue growth+53.2%
Cash$40.8M
Total assets$112.6M
P/E (computed)Net income was not positive
P/S (computed)13.8×

Warning signs

Cash runway
12.3 months
$26.5M cash at September 30, 2026
Share count, 1 year
+9.8%
2025-10-31 to 2026-11-09 · +44.6% over 3 years
Going-concern doubt
No
10-Q filed November 12, 2026
Insider net buying, 12 months
$24K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-12
Cash and burn$26.5M cash; operating cash flow -$6.5M a quarter.Report 2026-09-30
Shares outstanding252,954,764 (2026-11-09); 230,327,537 a year earlier; 174,986,671 three years earlier.Cover page 2026-11-09
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedownsLatest 2026-03-11
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorBaker Tilly US, LLP, San Diego, California, United States; changed auditors 1 time in 24 months8-K 4.01 2025-06-09
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $24K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$1.4M$4.2M-$5.6M$26.5MNo debt tags$10.8M10-Q 2026-11-12
Q2 2026
2026-06-30
$1.1M$1.5M-$7.2M$37.4MNo debt tags$13.1M10-Q 2026-08-06
Q1 2026
2026-03-31
$1.7M-$4.8M-$8.1M$35.9MNo debt tags$14.8M10-Q 2026-05-12
Q4 2025
2025-12-31
$6.6M$851K-$4.9M$40.8MNo debt tags$14.6M10-K 2026-03-05
Q3 2025
2025-09-30
$3.7M-$29.8M-$3.6M$40.5MNo debt tags$10.8M10-Q 2026-11-12
Q2 2025
2025-06-30
$2.8M-$30.5M-$5.5M$42.3MNo debt tags$10.9M10-Q 2026-08-06
Q1 2025
2025-03-31
$1.5M-$4.1M-$4.9M$47.9MNo debt tags$9.6M10-Q 2026-05-12
Q4 2024
2024-12-31
$2.9M-$3.3M-$6.3M$45.8MNo debt tags$9.5M10-K 2026-03-05

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32026-03-11
Latest annual report10-K2026-03-05
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-11-12
Latest proxyDEFA14A2026-04-29

Source: SEC EDGAR submissions feed, 1,004 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-10.8%
1 month0.0%
3 months-14.2%
Year to date-45.5%
1 year-49.4%
From 52-week high-53.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
IKTInhibikase Therapeutics Inc.$1.45-4.61%$203.4M
ARTVArtiva Biotherapeutics Inc.$3.96-1.25%$195.8M
CGENCompugen Ltd.$2.04-2.86%$193.0M
PALIPalisade Bio Inc.$1.03-8.04%$184.7M
CABACabaletta Bio Inc.$1.11-13.28%$239.4M
IVVDInvivyd Inc.$0.5377-7.63%$158.5M
PLXProtalix BioTherapeutics Inc. (DE)$3.03-0.66%$255.5M
IPHAInnate Pharma S.A. ADS$1.41-1.06%$156.9M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier